|
Feb 11
|
Why Biohaven Stock Triumphed on Tuesday
|
|
Feb 11
|
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
|
|
Feb 11
|
Why Biohaven (BHVN) Stock Is Rallying Today
|
|
Feb 11
|
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
|
|
Jan 3
|
Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares
|
|
Jan 2
|
Company News for Jan 2, 2025
|
|
Oct 3
|
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock
|
|
Oct 1
|
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
|
|
Sep 30
|
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
|
|
May 15
|
Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
|
|
May 14
|
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
|
May 13
|
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
|
May 9
|
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
|
|
Apr 26
|
Independent Director of Biohaven John Childs Buys 3.2% More Shares
|
|
Apr 26
|
3 Biotech Stocks to Buy on the Dip: April 2024
|
|
Apr 25
|
Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)
|
|
Apr 23
|
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)
|
|
Apr 22
|
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
|
|
Apr 18
|
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
|
|
Apr 17
|
Biohaven Announces Proposed Public Offering of Common Shares
|